The biotech landscape is witnessing significant shifts as former BioMarin Pharmaceuticals executives embark on a new venture, while GSK has made headlines with its...
Barclays has downgraded shares of Rapt Therapeutics (NASDAQ:RAPT) from an overweight rating to an equal weight rating, according to a research note published on...